DeFi Intel

Canton Network Funding Keeps Digital Asset at $2 Billion

Additional $10M from Shinhan and SC Ventures lifts Digital Asset’s round to $365M while keeping a $2B valuation. Canton incentives and builder funds come into focus.

TL;DR

Binance.US is pursuing a $100 million private round that could value it at $1 billion after a costly 2023 settlement, while AI drug‑discovery firm Isomorphic Labs is in talks for a valuation of at least $40 billion, reflecting a shift of capital toward regulated tech and biotech ventures.

Key facts

  • Binance.US seeks up to $100 million in a new funding round.
  • Binance Holdings paid $4.3 billion in penalties after a 2023 settlement.
  • Isomorphic Labs is discussing a valuation of at least $40 billion.
  • Isomorphic Labs raised $600 million in Series A (Mar 2025) and $2.1 billion in Series B (May 2026).

On July 22, 2026, Bloomberg reported that Binance.US is courting private investors for a new financing round that could raise as much as $100 million and place the U.S. exchange at a $1 billion valuation. The move follows a 2023 settlement that forced Binance Holdings Ltd. to pay $4.3 billion in penalties and accept heightened regulatory oversight. At the same time, Alphabet‑backed Isomorphic Labs, the AI drug‑discovery spin‑out of DeepMind, entered early talks to secure funding at a valuation of at least $40 billion, a figure that could climb toward $50 billion. Both companies are seeking fresh capital to expand operations and regain competitive footing after recent regulatory and market pressures.

Background

Binance.US, the American arm of the global crypto exchange Binance, previously secured a $200 million seed round in 2022 that valued the platform at $4.5 billion. The exchange’s growth was later hampered by a 2023 settlement between Binance Holdings Ltd. and U.S. authorities, which required a $4.3 billion penalty and introduced ongoing monitoring. The settlement also saw former CEO Changpeng Zhao plead guilty to a felony, serve a four‑month prison term, and receive a presidential pardon in 2025. Meanwhile, Isomorphic Labs emerged in 2021 as a DeepMind spin‑out focused on AI‑driven drug design, leveraging the AlphaFold protein‑folding technology. The startup raised a $600 million Series A in March 2025, led by Thrive Capital, and followed with a $2.1 billion Series B in May 2026, attracting investors such as Alphabet, Thrive Capital, and the UK Sovereign AI Fund. Its platform, IsoDDE, has attracted partnerships with major pharmaceutical firms including Eli Lilly, Novartis, and Johnson & Johnson, which have agreed to milestone‑based payments that could exceed $3 billion if development targets are met. Both firms are now pursuing new capital to scale their respective businesses amid evolving regulatory and competitive landscapes.

What happened

According to a Bloomberg report cited by Cointelegraph on July 22, 2026, Binance.US informed potential investors that it is seeking up to $100 million in private funding, a round that could value the exchange at $1 billion. The report notes that the exchange disclosed the round to World Liberty Financial, a crypto platform co‑founded by former President Donald Trump and his sons, but World Liberty will not participate. The funding effort is described as part of Binance.US’s strategy to recapture market share after the 2023 settlement that imposed a $4.3 billion penalty on its parent company and led to increased oversight. In a separate report from CryptoBriefing on the same day, Bloomberg is said to have revealed that Isomorphic Labs is in early discussions to raise capital at a valuation of at least $40 billion, with the possibility of reaching $50 billion. The article clarifies that these talks are preliminary and no deal has been finalized. Isomorphic’s most recent financing history includes a $2.1 billion Series B round in May 2026, following a $600 million Series A in March 2025, bringing its total disclosed external funding to roughly $2.7 billion since its founding. Both companies are therefore actively seeking new investment to fuel expansion and address recent challenges.

Market impact

The prospective $100 million infusion into Binance.US could provide the exchange with liquidity to expand its product suite and compete more aggressively with larger rivals in the U.S. market. If the $1 billion valuation materializes, it would represent a significant decline from the $4.5 billion pre‑money valuation recorded in 2022, potentially influencing investor sentiment toward crypto exchanges facing regulatory scrutiny. For Isomorphic Labs, the discussion of a $40 billion valuation—potentially rising to $50 billion—signals a dramatic increase from its prior $17.5 billion estimate and reflects the high premium investors are placing on AI‑driven drug discovery. The $2.1 billion Series B round in May 2026 and the earlier $600 million Series A illustrate a rapid scaling of capital inflows, which could affect biotech and AI market dynamics, especially as pharmaceutical partners stand to pay over $3 billion in milestone payments contingent on successful drug development. Both funding activities are likely to generate heightened trading volumes in related equities and tokens, as market participants adjust positions based on the perceived growth trajectories of these high‑profile entities.

Why it matters

The Binance.US funding round matters because it demonstrates how crypto platforms are attempting to rebound from heavy regulatory penalties and regain market relevance in a tightly supervised environment. The reduced valuation underscores the financial pressure the exchange faces, while the pursuit of private capital may set a precedent for other U.S. crypto firms seeking to navigate post‑settlement landscapes. Isomorphic Labs’ valuation talks highlight the escalating financial commitment to AI‑enabled drug discovery, a sector where capital intensity and regulatory milestones are tightly linked. The partnership agreements with Eli Lilly, Novartis, and Johnson & Johnson, coupled with the potential $3 billion in milestone payments, illustrate how biotech firms are leveraging AI to accelerate pipelines, which could reshape drug development economics if the technology delivers on its promise. Together, these developments reflect broader trends of capital reallocation toward regulated tech and biotech ventures, influencing investor allocation decisions across crypto, AI, and pharmaceutical markets.

DeFi Intel’s take

Editorial analysis, not a statement of fact.

DeFi Intel's take: the Binance.US financing effort suggests that even after a multi‑billion‑dollar settlement, crypto exchanges are still able to attract sizable private investment, albeit at markedly lower valuations. We read this as a signal that investors remain cautiously optimistic about the exchange’s ability to reclaim market share, provided it can demonstrate compliance and product growth. The Isomorphic Labs valuation talks, on the other hand, indicate that the market is willing to place very high bets on AI‑driven drug platforms, despite the lack of any patient dosing data. This suggests that capital is flowing toward speculative biotech ventures where the upside is tied to future milestone payments rather than current revenue. Both cases illustrate a broader shift: capital is being redeployed from traditional crypto projects toward regulated, high‑potential tech sectors, reflecting a risk‑adjusted search for growth in a post‑settlement regulatory environment.

Sources used for this analysis

DeFi Intel wrote this analysis from the reporting above. Any figure or quotation can be checked against those pages.

Frequently asked questions

Why is Binance.US seeking a new funding round?

Binance.US is looking to raise up to $100 million to regain market share after a 2023 settlement forced its parent company to pay $4.3 billion in penalties and accept tighter oversight, according to the Bloomberg report cited by Cointelegraph.

What valuation is Isomorphic Labs targeting in its latest funding talks?

Isomorphic Labs is reportedly in early discussions to secure financing at a valuation of at least $40 billion, with the possibility of reaching $50 billion, as detailed in the CryptoBriefing article referencing Bloomberg.

How have previous funding rounds shaped Isomorphic Labs' capital base?

The AI drug‑discovery startup raised $600 million in a Series A round in March 2025 and $2.1 billion in a Series B round in May 2026, bringing its disclosed external funding to roughly $2.7 billion since its founding.

Read full article on Cryptodaily →

DeFi Intel is an entity-graph aggregator: we curate, tag and link crypto news to a typed knowledge graph of protocols, tokens, people and incidents. We do not republish the full article body. Use the link above to read the original report at Cryptodaily.

Entities in this story

Discussion

Comments are reviewed before publication.

No comments yet.

Want the full article?

Continue reading on Cryptodaily →

Stay current on entity-tagged crypto news

Get the weekly DeFi Intel brief — entity-graph intelligence covering protocols, tokens and incidents, free to your inbox.